产品
编 号：F025121
分子式：C16H17N5O5
分子量：359.34
分子式：C16H17N5O5
分子量：359.34
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 1062444-54-5
产品详情
生物活性：
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.
体内研究：
The intravenous (IV) administration of the formulation to mice bearing 4T1 breast cancer tumors results in nanoparticle accumulation in tumors, reduction in primary tumor growth, and inhibition of lung metastases, as compared to saline-treated animals. Mice administered 1V209 experience significantly increases plasma levels of proinflammatory cytokines IL-6, IP-10, and MCP-1 at 2 h following IV administration.
体外研究：
1V209 (0.1-10 μM) treatment significantly stimulates TNFα production in RAW246.7 cells. 1V209 (18 hours) treatment increases IL-6 production comparain bone marrow derived dendritic cells.
1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. 1V209 can be conjugated with various polysaccharides to improve its water solubility, and enhance its efficacy, and maintain low toxicity.
体内研究：
The intravenous (IV) administration of the formulation to mice bearing 4T1 breast cancer tumors results in nanoparticle accumulation in tumors, reduction in primary tumor growth, and inhibition of lung metastases, as compared to saline-treated animals. Mice administered 1V209 experience significantly increases plasma levels of proinflammatory cytokines IL-6, IP-10, and MCP-1 at 2 h following IV administration.
体外研究：
1V209 (0.1-10 μM) treatment significantly stimulates TNFα production in RAW246.7 cells. 1V209 (18 hours) treatment increases IL-6 production comparain bone marrow derived dendritic cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备